PET Imaging Leader CTI Comments on Medicare Announcement of Broad Coverage for All Cancers
31 Enero 2005 - 10:25AM
PR Newswire (US)
PET Imaging Leader CTI Comments on Medicare Announcement of Broad
Coverage for All Cancers KNOXVILLE, Tenn., Jan. 31
/PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc.
(NASDAQ:CTMI), a leading provider of positron emission tomography
(PET) equipment, molecular biomarkers and services, commented on
the Centers for Medicare and Medicaid Services (CMS) final coverage
decision regarding expanded broad coverage for PET. CMS has
determined that sufficient evidence exists to conclude that an FDG
PET scan for the detection of pre-treatment metastases (i.e.,
staging) in newly diagnosed cervical cancer subsequent to
conventional imaging that is negative for extra-pelvic metastasis
is reasonable and necessary as an adjunct test. Further, CMS
announced that it intends to issue a national coverage
determination (NCD) for this indication. CMS's final coverage
decision announced on January 28, 2005 expands the use of PET in
brain, cervical, ovarian, pancreatic, small cell lung, and
testicular cancers and all other cancers that are not presently
covered. The CMS coverage policy will cover these PET scans when
the provider participates in either a PET clinical trial, or
submits data to an FDG PET registry designed to provide additional
information on the benefits of PET for diagnosis, staging,
restaging and monitoring of therapeutic response. Ronald Nutt,
Ph.D., President and Chief Executive Officer, commented on the
announcement, "Medicare reimbursement of PET imaging for cancer
will give hope to thousands of Americans and their families. Now
patients will get the best treatment available as a result of this
important decision. Currently approximately seventy percent of all
cancers have some coverage for PET scans. This announcement
broadens coverage for those indications by including monitoring of
therapeutic response. In addition those cancers not previously
covered by Medicare will now be covered." About CTI Molecular
Imaging: CTI Molecular Imaging, Inc. is a leading supplier of
products and services for positron emission tomography (PET), a
diagnostic imaging technology used in the detection and treatment
of cancer, neurological disorders and cardiac disease. Additional
information is available at: http://www.ctimi.com/ . About PET and
PET/CT: PET images the biology of diseases at the molecular level,
often before changes are visible by anatomical imaging or, in some
cases, before symptoms appear. Diseases are biological processes
and it is these processes that PET examines. PET/CT combines the
biological examination of patients by PET with CT images of the
body's structural detail. PET/CT technology improves the diagnostic
accuracy and treatment management of patients by providing
surgeons, radiation oncologists and other physicians with precise
anatomical landmarks associated with the disease condition as
determined by PET. PET's whole-body imaging capability helps
physicians improve their ability to detect and determine the
location, extent and stage of cancer, neurological disorders and
cardiac disease. By improving diagnosis, PET scans aid physicians
in selecting better courses of treatment, as well as assessing
whether treatment is effective or should be changed. Recent
published clinical trials have shown that in a wide array of
cancers, the use of PET has caused the treatment to be changed for
15 to 50% of patients, depending on the specific clinical question.
In addition, PET and PET/CT provide both the patient and their
physician with a degree of certainty that is often unavailable
through other imaging methods. Certain matters discussed in this
press release constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements, which may be identified by words
such as "believe," "expect," "anticipate," "intend," "estimate" or
similar expressions, include statements regarding CTI's financial
outlook for 2005, future demand for scanners, the impact of
reimbursement levels and coverage decisions for PET, future pricing
trends and any other statements that necessarily depend on future
events. Forward-looking statements involve a number of risks and
uncertainties and there can be no assurance that any
forward-looking statements will prove to be accurate. CTI
undertakes no obligation to update or revise any forward-looking
statements. Further information regarding risks, uncertainties and
other factors that could adversely affect CTI or cause actual
results to differ materially from those anticipated in
forward-looking statements are included in CTI's Annual Report on
Form 10-K for the fiscal year ended September 30, 2004. DATASOURCE:
CTI Molecular Imaging, Inc. CONTACT: Lisa Baird of CTI Molecular
Imaging, Inc., +1-865-218-2000 Web site: http://www.ctimi.com/
Copyright
Cti Molecular Imaging (NASDAQ:CTMI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cti Molecular Imaging (NASDAQ:CTMI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024